AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9664766 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg) orally
Number of subjects: 30
Study 9664766 — intervention group
Group type: COMPARATOR
Intervention: Atropine sulfate (0.01 mg/kg) and hydroxyzine hydrochloride (1mg/kg) intramuscularly
Number of subjects: 30
Study 8565037 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg once daily
Number of subjects: 328
Study 8565037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1000 mg once daily
Number of subjects: 328
Study 8565037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 2014945 — intervention group
Group type: EXPERIMENTAL
Intervention: PEU‐Vialon catheter
Number of subjects: 1054
Study 2014945 — intervention group
Group type: COMPARATOR
Intervention: FEP‐Teflon catheter
Number of subjects: 1054
Study 2014945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 1054
Study 2014945 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1054
Study 2014945 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged catheterization (greater than 48 hours)
Number of subjects: 1054
Study 2014945 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-related infection
Number of subjects: 1054
Study 2014945 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebitis with a previous catheter
Number of subjects: 1054
Study 2014945 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic site (hand: forearm)
Number of subjects: 1054
Study 2014945 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic site (wrist: forearm)
Number of subjects: 1054
Study 7082151 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 43
Study 7082151 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 7082151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic
Number of subjects: 43
Study 7082151 — intervention group
Group type: EXPERIMENTAL
Intervention: Static
Number of subjects: 43
Study 7082151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstrings
Number of subjects: 43
Study 7082151 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk
Number of subjects: 43
Study 31863182 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive multicomponent behavioral treatment (Beh)
Number of subjects: 579
Study 31863182 — intervention group
Group type: COMPARATOR
Intervention: Combination of behavioral treatment and medication management (Comb&MedMgt)
Number of subjects: 579
Study 31863182 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (Comb)
Number of subjects: 579
Study 28701360 — intervention group
Group type: EXPERIMENTAL
Intervention: Early resumption of non-contact physical activity beginning 72 hours postinjury
Number of subjects: 350
Study 28701360 — intervention group
Group type: COMPARATOR
Intervention: Rest until fully asymptomatic
Number of subjects: 350
Study 28244952 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic phenylephrine infusion
Number of subjects: 506
Study 28244952 — intervention group
Group type: COMPARATOR
Intervention: Vasopressor bolus strategy (Control)
Number of subjects: 506
Study 25526101 — intervention group
Group type: EXPERIMENTAL
Intervention: 27‐gauge transconjunctival nonvitrectomizing vitreous surgery (NVS)
Number of subjects: 83
Study 25526101 — intervention group
Group type: COMPARATOR
Intervention: 25‐gauge transconjunctival sutureless vitrectomy surgery (Standard)
Number of subjects: 83
Study 25015006 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 μg/kg every 6 hours
Number of subjects: 50
Study 25015006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22982947 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led education program on HIV prevention
Number of subjects: 276
Study 19568195 — intervention group
Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 50
Study 19568195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount/moderate-intensity and low-amount/vigorous-intensity
Number of subjects: 50
Study 19568195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount/vigorous-intensity
Number of subjects: 50
Study 19568195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount groups combined
Number of subjects: 50
Study 19568195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount group
Number of subjects: 50
Study 17689632 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated shoulder dystocia
Number of subjects: 140
Study 15226624 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 70
Study 15226624 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 11273845 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triacylglycerol
Number of subjects: 35
Study 11273845 — intervention group
Group type: COMPARATOR
Intervention: Cocoa butter
Number of subjects: 35
Study 11273845 — intervention group
Group type: COMPARATOR
Intervention: High-oleate sunflower oil (oleate)
Number of subjects: 35
Study 9883467 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 million units of interferon alpha-2b
Number of subjects: 75
Study 9883467 — intervention group
Group type: COMPARATOR
Intervention: 3 million units of interferon alpha-2b
Number of subjects: 75
Study 7983296 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of SF-36
Number of subjects: 100
Study 7983296 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face administration of SF-36
Number of subjects: 100
Study 1753728 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility training (3 times per week, 20-30 minutes for 10 weeks)
Number of subjects: 20
Study 1753728 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training, alternative exercise program including walking, swimming, dance, and other locomotor activities)
Number of subjects: 20
Study 7019928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisomicin (2.5 to 4.0 mg/kg per day for 5 to 21 days)
Number of subjects: 55
Study 7019928 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (2.5 to 4.0 mg/kg per day for 5 to 21 days)
Number of subjects: 55
Study 7019928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisomicin
Number of subjects: 55
Study 7019928 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 55
Study 30811909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 647
Study 30811909 — intervention group
Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 647
Study 29344387 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI) 40 U daily or 80 U every other day for 8 weeks, followed by open-label extension with 16, 40 or 80 U RCI 1-3 times/week for 52 weeks.
Number of subjects: 38
Study 29344387 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks, followed by RCI in the open-label extension.
Number of subjects: 38
Study 26095443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitative care (task-oriented exercises, cognitive-behavioral training, and occupational therapy)
Number of subjects: 70
Study 26095443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitative care
Number of subjects: 70
Study 26095443 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy (control)
Number of subjects: 70
Study 23702855 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° shoulder abduction with elbow extension (90 ABD)
Number of subjects: 60
Study 23702855 — intervention group
Group type: EXPERIMENTAL
Intervention: 130° shoulder abduction with elbow flexion at 110° (130 ABD)
Number of subjects: 60
Study 23702855 — intervention group
Group type: EXPERIMENTAL
Intervention: 150° shoulder abduction with elbow extension (150 ABD)
Number of subjects: 60
Study 23702855 — intervention group
Group type: EXPERIMENTAL
Intervention: 170° shoulder abduction with elbow extension (170 ABD)
Number of subjects: 60
Study 21237455 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 40
Study 21237455 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 40
Study 18069061 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 78
Study 18069061 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 17415652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy (including interferon monotherapy, pegylated-interferon monotherapy, consensus-interferon, interferon + ribavirin, pegylated-interferon + ribavirin)
Number of subjects: 56
Study 17415652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 56
Study 15234664 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% paromomycin plus 12% methylbenzonium chloride (PR‐MBCL) applied twice daily for 30 days
Number of subjects: 120
Study 15234664 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% paromomycin plus 10% urea (PR‐U) applied twice daily for 30 days
Number of subjects: 120
Study 15234664 — intervention group
Group type: COMPARATOR
Intervention: 20mg/kg/day of IM meglumine antimoniate (MA) for 10 days
Number of subjects: 120
Study 11398169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors as second-line therapy for postmenopausal women with advanced breast cancer progressing during tamoxifen therapy.
Number of subjects: 0
Study 11398169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors as first-line therapy in place of tamoxifen.
Number of subjects: 0
Study 11398169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors in the prevention of breast cancer and in neoadjuvant and adjuvant treatment of early-stage breast cancer.
Number of subjects: 0
Study 9533048 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted autograft (90 degrees of external twist)
Number of subjects: 120
Study 9533048 — intervention group
Group type: COMPARATOR
Intervention: Nontwisted autograft (control)
Number of subjects: 120
Study 9533048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (twist and control)
Number of subjects: 120
Study 7989475 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 4 months; mean BMI of treated subgroup: 42.7 ± 4.3 kg/m2.
Number of subjects: 31
Study 3044515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosquito nets
Number of subjects: 190
Study 3044515 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil hydrochloride (100 mg daily according to weight)
Number of subjects: 190
Study 3044515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 or 2 tablets daily)
Number of subjects: 190
Study 31126123 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 32
Study 31126123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 32
Study 29202258 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed sedation using dexmedetomidine
Number of subjects: 0
Study 29202258 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (standard care)
Number of subjects: 0
Study 26159436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radial artery catheterization
Number of subjects: 125
Study 26159436 — intervention group
Group type: COMPARATOR
Intervention: Direct palpation radial artery catheterization
Number of subjects: 125
Study 23419341 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope
Number of subjects: 30
Study 23419341 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 30
Study 21198772 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.35 mg kg(‐1))
Number of subjects: 0
Study 21198772 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.035 mg kg(‐1))
Number of subjects: 0
Study 21198772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.30 mg kg(‐1))
Number of subjects: 0
Study 18220290 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a plus oral placebo for 48 weeks
Number of subjects: 271
Study 18220290 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Number of subjects: 271
Study 18220290 — intervention group
Group type: COMPARATOR
Intervention: HBV DNA
Number of subjects: 271
Study 16154709 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 63
Study 16154709 — intervention group
Group type: COMPARATOR
Intervention: Non-PTSD subjects
Number of subjects: 63
Study 16154709 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 63
Study 16154709 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cortisol secretion (AUC(G))
Number of subjects: 63
Study 14583678 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (24 mg) with Quinidine (800 mg)
Number of subjects: 20
Study 14583678 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (24 mg) without Quinidine (placebo)
Number of subjects: 20
Study 10975630 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.62 g/kg)
Number of subjects: 8
Study 10975630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9383184 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg sustained-release verapamil
Number of subjects: 1414
Study 9383184 — intervention group
Group type: COMPARATOR
Intervention: 25 mg chlorthalidone
Number of subjects: 1414
Study 1388337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg IV)
Number of subjects: 66
Study 1388337 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (1.25 mg IV)
Number of subjects: 66
Study 1388337 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg IV)
Number of subjects: 66
Study 3890014 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 33
Study 3890014 — intervention group
Group type: COMPARATOR
Intervention: Hypaque (diatrizoate sodium and diatrizoate meglumine)
Number of subjects: 33
Study 29909432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 50 mg sildenafil
Number of subjects: 12
Study 29909432 — intervention group
Group type: EXPERIMENTAL
Intervention: Supralingual administration of 50 mg sildenafil
Number of subjects: 12
Study 27590190 — intervention group
Group type: EXPERIMENTAL
Intervention: Major PAD
Number of subjects: 11140
Study 27590190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity ulceration or amputation
Number of subjects: 11140
Study 24141253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed and bedside chair pressure sensors using radio-pagers
Number of subjects: 1839
Study 24141253 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1839
Study 22776958 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant human erythropoietin (rEpo) 3 × 3,000 U/kg within 42 h after birth
Number of subjects: 0
Study 21147867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)
Number of subjects: 167
Study 21147867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Irinotecan (CPT-11)
Number of subjects: 167
Study 21147867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) and Bevacizumab + Irinotecan (CPT-11)
Number of subjects: 167
Study 17432275 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 0
Study 17432275 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 0
Study 16109111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg plus naproxen sodium 500 mg
Number of subjects: 972
Study 16109111 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 972
Study 16109111 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium 500 mg
Number of subjects: 972
Study 16109111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 972
Study 12324670 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (PAV) during exercise training
Number of subjects: 19
Study 12324670 — intervention group
Group type: COMPARATOR
Intervention: Unaided exercise training
Number of subjects: 19
Study 10457687 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-coated lenses (Crizal)
Number of subjects: 19
Study 10457687 — intervention group
Group type: COMPARATOR
Intervention: Uncoated lenses
Number of subjects: 19
Study 7593498 — intervention group
Group type: EXPERIMENTAL
Intervention: Humegon (225 IU)
Number of subjects: 9
Study 7593498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergonal (225 IU)
Number of subjects: 9
Study 7593498 — intervention group
Group type: COMPARATOR
Intervention: Both preparations
Number of subjects: 9
Study 1701802 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 3 injections/week for 13 weeks)
Number of subjects: 12
Study 1701802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent block therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 4 cycles of 5 injections on days 1, 3, 5, 7, and 9)
Number of subjects: 12
Study 1701802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent single-dose therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 6 cycles of 1 injection on day 1)
Number of subjects: 12
Study 6988175 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg nitrofurantoin plus 150 mg sulphadiazine 3-times daily
Number of subjects: 177
Study 6988175 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nitrofurantoin plus 500 mg sulphadiazine 3-times daily
Number of subjects: 177
Study 6988175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dosage group (50 mg nitrofurantoin plus 150 mg sulphadiazine)
Number of subjects: 177
Study 31983583 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF) intervention
Number of subjects: 0
Study 31983583 — intervention group
Group type: COMPARATOR
Intervention: Health facilities receiving intensified Polio Eradication Initiative (PEI)
Number of subjects: 0
Study 31983583 — intervention group
Group type: COMPARATOR
Intervention: Unconditional financial and technical assistance
Number of subjects: 0
Study 31983583 — intervention group
Group type: EXPERIMENTAL
Intervention: PBF intervention
Number of subjects: 0
Study 31176392 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified SAE implants (test group)
Number of subjects: 20
Study 31176392 — intervention group
Group type: COMPARATOR
Intervention: SAE implants (control group)
Number of subjects: 20
Study 28642466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual task gait training (CDTT)
Number of subjects: 28
Study 28642466 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor dual task gait training (MDTT)
Number of subjects: 28
Study 28642466 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 28
Study 25586372 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel prewarmed to 42°C (W group)
Number of subjects: 74
Study 25586372 — intervention group
Group type: COMPARATOR
Intervention: i-gel kept at room temperature (C group)
Number of subjects: 74
Study 22181693 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Terbinafine Nail Solution (TNS)
Number of subjects: 0
Study 22181693 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 22181693 — intervention group
Group type: COMPARATOR
Intervention: Amorolfine 5% nail lacquer
Number of subjects: 0
Study 21212216 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 132
Study 21212216 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 132
Study 20002088 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 30
Study 20002088 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 30
Study 20002088 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg)
Number of subjects: 30
Study 20002088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 30
Study 20002088 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (10 mg)
Number of subjects: 30
Study 20002088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail of all five drugs
Number of subjects: 30
Study 17155989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 2425
Study 17155989 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 2425
Study 17155989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil to Tadalafil
Number of subjects: 2425
Study 17155989 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil to Sildenafil
Number of subjects: 2425
Study 17155989 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Preference
Number of subjects: 2425
Study 15198743 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 7
Study 15198743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 7
Study 12171082 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 9696971 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 141
Study 9696971 — intervention group
Group type: COMPARATOR
Intervention: Subtotal thyroidectomy
Number of subjects: 141
Study 9696971 — intervention group
Group type: COMPARATOR
Intervention: Completion thyroidectomy
Number of subjects: 141
Study 10155594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 0
Study 10155594 — intervention group
Group type: COMPARATOR
Intervention: Control (no lenograstim)
Number of subjects: 0
Study 2502251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing L-alanine and glucose
Number of subjects: 97
Study 2502251 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose based oral rehydration solution
Number of subjects: 97
Study 1012910 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intermittency with random wave pattern of 9.76 cpm and magnitudes of 0.0, 0.2, 0.4, 0.6, 0.8, 1.0, and 1.5 sec.
Number of subjects: 0